<DOC>
	<DOC>NCT01894399</DOC>
	<brief_summary>Study Design - Open, escalating single-dose design. - 7 ascending dose cohorts - In each cohorts, subjects will receive a single dose of HM61713. - Main objective of this study is to evaluate the pharmacokinetics of HM61713 tablet.</brief_summary>
	<brief_title>Study to Evaluate a Pharmacokinetic of HM61713 in Healthy Male Subjects</brief_title>
	<detailed_description>Primary objectives • To assess the PK characteristics of HM61713 and metabolites in healthy male volunteers Secondary objectives - To assess the safety and tolerability of HM61713 tablet in healthy male subjects. - To assess the food effect on PK characteristics of HM61713 tablet in healthy male subjects. - To assess the ethnic differences of PK characteristics of HM61713 (Korean, Japanese, Caucasian) - To investigate genotype of drug metabolism.transport that affect PK characteristics of HM61713 - To investigate the change of endogenous metabolic markers after administration of HM61713</detailed_description>
	<criteria>Healthy male volunteers, age between 20 and 45 Informed of the investigational nature of this study and voluntarily agree to participate in this study BMI of ＞18.5kg/m2 and ＜28kg/m2 subject Use of any prescription medication within 2 weeks prior to Day 1 Use of any medication within 1 weeks prior to Day 1 Has a severe medical history of hypersensitivity to drug Participation in another clinical study within 8 weeks days prior to start of study drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HM61713</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Phase I</keyword>
	<keyword>healthy</keyword>
	<keyword>olmutinib</keyword>
</DOC>